Axogen Q1 revenue up 18% to $36.7M; net loss narrows; FDA clears Axoguard HA+

Axogen, Inc.

2023-Q1 EPS reported -$0.17 revenue$36,664,000

Net revenue $36.7M (+18% YoY); net loss $7.1M vs $11.5M prior year.
Adjusted net loss $4.1M ($0.10/share) vs $8.5M ($0.20/share) prior year.
FDA 510(k) clearance for Axoguard HA+ Nerve Protector; pilot launch Q2, full launch Q3.
Full-year 2023 revenue guidance reaffirmed at $154M-$159M.
Cash and investments $44.1M at March 31, down from $55.0M at Dec 31, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axogen, Inc. reported first quarter ended March 31, 2023 results: revenue $36.7 million, net income $7.1 million, EPS $0.17 per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $36.7 million
Net income: $7.1 million
EPS: $0.17 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

today reported financial results and business highlights for the first quarter ended March 31, 2023. First Quarter Financial Results and Business Highlights • Net revenue was $36.7 million, an increase of 18% over the first quarter of 2022. • Gross margin was 81.7%, compared to 82.1% in the first quarter of 2022. • Net loss of $7.1 million, or $0.17 per share,

View on SEC.gov

Browse all earnings releases →

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-23-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.